Osteoarthritis Hand
Conditions
Keywords
SAMe, S-Adenosyl-L-Methionine
Brief summary
The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.
Detailed description
At week 0, all patients giving written informed consent and meeting eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to SAMe (400mg orally, twice daily) or placebo (400mg, twice daily) for 8 weeks. Followed by a one week wash out period followed by another 8 weeks of SAMe (400mg, twice daily) or placebo (400mg, twice daily) for 8 weeks (whichever was not given during the first 8 week period). Participants will complete weekly surveys during the entire study regarding hand discomfort, functional limitations and side effects
Interventions
DRUGS-Adenosyl-L-Methionine (Sam-E)
400 mg capsule
DRUGPlacebo
400 mg identically appearing placebo
Sponsors
Dartmouth-Hitchcock Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Current primary care provider within the Dartmouth Health system * Office visit at Dartmouth Health in the past 3 years * Participants must be 40 or older at the time of signing the informed consent * Participants have discomfort or functional limitations of one or both hands AND either: 1. Objective findings of at least one hand meeting diagnostic criteria based on the American College of Rheumatology (ACR)\* or 2. Existing radiographic evidence of osteoarthritis as judged by a radiologist * Patients taking OTC or prescription analgesics who are willing to stop their current analgesics for two weeks prior to study entry and remain off those medications over the course of the study * \*Objective inclusion criteria (see poster schematic) Swelling or deformity of 2 of the following ten joints: the 2nd and 3rd distal interphalangeal (DIP) of each hand, the 2nd and 3rd proximal interphalangeal (PIP) of each hand, and the 1st carpometacarpal joints of both hands.
Exclusion criteria
* Patients taking prescription medications other than NSAIDs for their OA who are unable to stop their medication * Patients with diagnoses of arthritis from conditions other than OA * Patients whose symptomatic joint is an artificial joint * Patients with Bipolar Disorder * Patients taking any of the following medications at study entry OR starting any of these medications during the study period: 1. daily opioids (including tramadol or buprenorphine) 2. gabapentin or pregabalin 3. prednisone 4. Prescription NSAIDs that they are unable to stop or topical diclofenac 5. SNRI drugs (Effexor, Cymbalta, Fetzima, Pristiq) * The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the effect of SAMe supplements on hand discomfort relative to placebo, as measured by the change in discomfort scores over time on a visual analog scale | Weekly for 17 weeks | Scores range from 0-10, 0 being no discomfort and 10 being maximum discomfort |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine the effect of SAMe supplementation on quality of life measures regarding hand arthritis, as measured by DASH (Disability of Arm, Shoulder and Hand) survey responses done weekly for 17 weeks | Weekly for 17 weeks | Survey using descriptors of disability and function ranging from no disability to complete disability with 3 other levels of disability in between done weekly for 17 weeks |
| Determine tolerability of SAMe supplementation compared to placebo, as measured by a survey of 14 common symptoms one may experience from a supplement | Weekly for 17 weeks | 14 symptoms queried for occurrence over the week ranging from Not at All to Very Much with three additional options in between |
Countries
United States
Outcome results
None listed